HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs ® to Accelerate Development of RNA-Guided Therapeutics Platform
'Moving our U.S. site to Lilly Gateway Labs marks an important step in the scale-up of our operations,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics.
Share
'Moving our U.S. site to Lilly Gateway Labs marks an important step in the scale-up of our operations,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. 'The facility offers world-class infrastructure and access to a dynamic scientific environment, providing an ideal setting to continue to advance our RNA-guided therapeutics platform, which is designed to reprogram the root causes of disease with unmatched precision, speed and scalability.'
Lilly Gateway Labs, which is part of the Lilly Catalyze360™ model, is a best-in-class innovation hub that connects early-stage biotech companies to the power of Lilly's expertise. The site offers cutting-edge laboratory space, operational support and access to an evolving ecosystem of biotech innovators.
HAYA's San Diego office plays a central role in the company's laboratory operations, with a strong focus on advanced multi-modal functional genomics, one of the key components of HAYA's proprietary platform and its Regulatory Genome Atlas. The office will also support business and clinical development, including the advancement of HAYA's first-in-class long non-coding RNA (lncRNA)-targeting therapy HTX-001 for heart failure into the clinic with an initial focus on non-obstructive hypertrophic cardiomyopathy.
HAYA recently announced a $65 million Series A financing to accelerate the development of RNA-guided therapeutics that target the regulatory genome to treat chronic and age-related diseases. The round was co-led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly) and Alexandria Venture Investments, the venture arm of Alexandria Real Estate Equities, Inc.
At the core of HAYA's platform is the ability to map and decode the regulatory genome. HAYA has built the most comprehensive atlas of the regulatory genome by combining multi-modal functional genomics with proprietary computational and machine learning tools. This allows for the precise identification and modulation of pathogenic cell states across a range of diseases. Last year, HAYA announced a collaboration with Lilly focused on RNA-based drug targets for obesity and related metabolic disorders, making it one of the largest collaborations to date in the regulatory genome field.
With its platform, HAYA is advancing a novel approach to develop next-generation precision medicines, and advance its mission of translating deep genomic, epigenomic and transcriptomic insights into novel disease-modifying therapies with potential to improve patients' outcomes by directly reprogramming the cellular drivers of disease.
HAYA Therapeutics remains fully independent and retains all assets and intellectual property while at Lilly Gateway Labs.
About HAYA Therapeutics
HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues.
HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego. For more information on the company, please visit our website at www.hayatx.com. Follow us on X and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
3 Penny Stocks With Market Caps Larger Than $10M To Watch
As major U.S. indexes continue their upward trajectory, buoyed by strong corporate earnings and resilient economic data, investors are exploring various avenues for potential growth. Penny stocks, though an older term in the investment lexicon, remain relevant as a category that encompasses smaller or newer companies with lower price points. When these stocks are backed by robust financials and solid fundamentals, they can present unique opportunities for growth that might be overlooked in more traditional investment sectors. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.66 $640.14M ★★★★★★ CuriosityStream (CURI) $4.59 $259.69M ★★★★★★ WM Technology (MAPS) $0.9048 $157.25M ★★★★★★ Tuniu (TOUR) $0.9326 $96.34M ★★★★★★ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.8906 $6.51M ★★★★★★ Lifetime Brands (LCUT) $4.44 $103.55M ★★★★★☆ Resources Connection (RGP) $4.98 $169.03M ★★★★★★ TETRA Technologies (TTI) $3.91 $508.34M ★★★★★★ Tandy Leather Factory (TLF) $3.45 $30.22M ★★★★★★ Click here to see the full list of 413 stocks from our US Penny Stocks screener. Here's a peek at a few of the choices from the screener. MediciNova Simply Wall St Financial Health Rating: ★★★★★★ Overview: MediciNova, Inc. is a biopharmaceutical company that develops novel small molecule therapeutics for serious diseases with unmet medical needs in the United States, with a market cap of $65.23 million. Operations: MediciNova, Inc. currently does not report any revenue segments. Market Cap: $65.23M MediciNova, Inc., a pre-revenue biopharmaceutical company with a market cap of US$65.23 million, is advancing its clinical pipeline despite financial challenges. The company remains debt-free and has sufficient cash runway for over three years. Recent updates highlight nearing completion of key trials for MN-166 and MN-001, targeting serious diseases like ALS and fatty liver disease. Although unprofitable with net losses reported at US$2.86 million in Q1 2025, MediciNova's seasoned management and board offer stability as it navigates the volatile penny stock landscape while holding Orphan Drug Designations for several treatments from the FDA and EU EMA. Click here and access our complete financial health analysis report to understand the dynamics of MediciNova. Understand MediciNova's earnings outlook by examining our growth report. Vasta Platform Simply Wall St Financial Health Rating: ★★★★★★ Overview: Vasta Platform Limited offers educational printed and digital solutions to private schools in Brazil's K-12 sector, with a market cap of $330.47 million. Operations: The company generates revenue through its Educational Services segment, specifically in Education & Training Services, amounting to R$1.64 billion. Market Cap: $330.47M Vasta Platform Limited, with a market cap of $330.47 million, operates in Brazil's K-12 educational sector and has recently become profitable, though its earnings are forecast to decline by an average of 55.2% annually over the next three years. Trading at a value below its estimated fair value and compared to peers, Vasta's financial health is supported by satisfactory debt levels and interest coverage. However, recent results show a net loss of R$3.27 million for Q1 2025 against revenue declines from the previous year. Management experience remains unclear while one-off gains have impacted past earnings quality. Unlock comprehensive insights into our analysis of Vasta Platform stock in this financial health report. Gain insights into Vasta Platform's future direction by reviewing our growth report. Hugoton Royalty Trust Simply Wall St Financial Health Rating: ★★★★★★ Overview: Hugoton Royalty Trust operates as an express trust in the United States with a market cap of $14.40 million. Operations: The trust's revenue is derived from its Oil & Gas - Exploration & Production segment, totaling $0.01 million. Market Cap: $14.4M Hugoton Royalty Trust, with a market cap of US$14.40 million, operates in the oil and gas sector but remains pre-revenue with earnings for Q1 2025 at just US$2,407. The trust is unprofitable yet has managed to reduce losses over five years by 28.4% annually. Despite its debt-free status and stable shareholder base without recent dilution, the stock's high volatility poses risks for investors. Recent changes include appointing Grant Thornton LLP as the new auditor after dismissing PwC and experiencing delays in SEC filings, reflecting potential operational challenges amidst an already unstable financial position. Jump into the full analysis health report here for a deeper understanding of Hugoton Royalty Trust. Understand Hugoton Royalty Trust's track record by examining our performance history report. Make It Happen Navigate through the entire inventory of 413 US Penny Stocks here. Want To Explore Some Alternatives? The end of cancer? These 25 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include MNOV VSTA and HGTX.U. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Time Business News
2 days ago
- Time Business News
Ford: A Timeless Journey of Innovation, Strength, and Legacy
Few automotive brands carry the weight of history and innovation quite like Ford. It's more than just a company—it's a global icon, a symbol of progress, and a trusted name woven into the fabric of modern society. From the roaring engines of classic muscle cars to the silent hum of next-gen electric vehicles, Ford represents a legacy of freedom, reliability, and bold vision. For over a century, Ford has stood as a pioneer of both industry and imagination. Whether you're cruising down a coastal highway or hauling heavy loads across rugged terrain, Ford drives dreams forward—generation after generation. In 1903, a visionary named Henry Ford changed the course of transportation forever. He didn't just build cars—he built a movement. Ford believed that every individual, not just the wealthy, deserved access to mobility. This dream gave birth to the Model T, the car that put the world on wheels. What truly set Ford apart was the introduction of the moving assembly line in 1913. This groundbreaking innovation reduced manufacturing time, lowered costs, and allowed Ford to pay workers fair wages. It wasn't just a business decision—it was a social revolution. In many ways, Ford helped shape the modern middle class. What began in a modest Detroit workshop has grown into a global powerhouse. Today, Ford operates in more than 100 countries, with production plants, design studios, and dealerships around the globe. Each region sees its piece of the Ford experience—from compact cars in Asia to heavy-duty trucks in the Americas. But despite its global presence, Ford maintains its core identity: durability, innovation, and customer trust. That's why you'll see a Ford at a dusty construction site in Texas, a rally course in Kenya, or a city street in London—proving that Ford is truly built for every road, every driver. Ford's legacy is one of constant reinvention. While honoring its heritage, Ford has always had one foot in the future. Recent years have seen an incredible wave of technological innovation: Ford Co-Pilot360™ : A suite of advanced driver-assist features like automatic emergency braking, blind-spot monitoring, and lane-keeping systems—all designed to keep drivers safer and more confident behind the wheel. : A suite of advanced driver-assist features like automatic emergency braking, blind-spot monitoring, and lane-keeping systems—all designed to keep drivers safer and more confident behind the wheel. SYNC Infotainment System : Voice-activated technology, navigation, Apple CarPlay, Android Auto, and cloud-connected features bring cutting-edge tech to your fingertips. : Voice-activated technology, navigation, Apple CarPlay, Android Auto, and cloud-connected features bring cutting-edge tech to your fingertips. FordPass™ App: A smartphone gateway to remote start, lock/unlock, locate your vehicle, schedule service appointments, and more. Innovation isn't a trend for Ford—it's part of its DNA. The automotive world is shifting, and Ford is leading the charge—literally. With a multi-billion-dollar investment in electric vehicle (EV) infrastructure, Ford is committed to a cleaner, brighter, and more efficient future. Mustang Mach-E : This all-electric SUV combines the soul of the iconic Mustang with the sustainability of the future's sleek, silent—and pure adrenaline. : This all-electric SUV combines the soul of the iconic Mustang with the sustainability of the future's sleek, silent—and pure adrenaline. F-150 Lightning : The beloved pickup, reborn as an all-electric powerhouse. With dual motors, instant torque, and even the ability to power your home, it's redefining what a truck can be. : The beloved pickup, reborn as an all-electric powerhouse. With dual motors, instant torque, and even the ability to power your home, it's redefining what a truck can be. E-Transit Van: Designed for commercial use, this EV delivers zero-emissions transport without sacrificing payload or functionality. Ford is more than ready for tomorrow—it's building it today. If there's one phrase that perfectly defines Ford's spirit, it's 'Built Ford Tough.' Ford's lineup of trucks—especially the iconic F-Series—has been trusted by hard-working individuals for generations. The Ford F-150, in particular, is the best-selling vehicle in the United States for over 40 years. It's not just popular; it's legendary. With exceptional towing capacity, military-grade aluminum alloy construction, hybrid powertrain options, and rugged styling, it's built for those who demand power, performance, and perseverance. Ford understands that authentic leadership means protecting the world we share. That's why sustainability is a core focus: Committed to carbon neutrality by 2050 Manufacturing plants powered by renewable energy Use of recycled and sustainable materials in new vehicle production in new vehicle production Innovation in battery technology and EV charging infrastructure Ford isn't just adapting to environmental responsibility—it's setting the standard. For millions, owning a Ford is more than transportation—it's a relationship. It's the car that taught your teenager to drive, the truck that hauled your first home, the Mustang that turned heads, or the van that took your family on summer road trips. Ford vehicles are in the photos of your memories, in the heart of your journeys, and in the conversations passed down from one generation to the next. This emotional bond is what makes Ford timeless. From Steve McQueen's 1968 Mustang in Bullitt to Will Smith's futuristic Ford GT in I, Robot , Ford has become a pop culture icon. Songs, movies, video games—you'll find Ford roaring across them all. That's because Ford is more than a car—it's a character, a symbol, and a source of inspiration. With over a century of legacy, innovation, and trust, Ford remains a brand like no other. It's a company that stays true to its roots while courageously reimagining the future. Whether you're a die-hard Mustang enthusiast, a rugged F-150 driver, or a first-time EV owner, Ford welcomes you with open arms—and an open road. Because with Ford, the drive never ends. TIME BUSINESS NEWS
Business Upturn
2 days ago
- Business Upturn
SmartVascular Dx™ Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS
IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States. We are proud to share that we have been included in the Medicare fee schedule, allowing us to offer national Medicare coverage along with our new partnerships with CareSource and HealthPartners. The SmartVascular Dx test provides a significant clinical advantage by accurately detecting vascular inflammation, a crucial factor in assessing cardiovascular risk. In a healthcare landscape increasingly focused on preventive strategies, this test supports early intervention, aligning seamlessly with the commitment to proactive healthcare in the region. We encourage physicians in the northeastern United States to seize this opportunity to offer the SVDx test to their patients. By identifying vascular risks earlier, healthcare providers can implement timely interventions, ultimately saving lives and improving health outcomes. Furthermore, we are excited to announce our partnership with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact [email protected] 866.299.8998 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
